Given this context, the present study aims to estimate the incremental cost-effectiveness ratio (ICER) of the FSL system in comparison to SMBG in T1DM and T2DM patients that require intensive insulin therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.